🔗 Share this article

As the US undertakes historic revisions to its immunization schedules, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 vaccinations during the pandemic and has concentrated on possible fatalities following COVID-19 immunization in her short tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to reveal major revisions to the childhood immunization program recently, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of alignment with a large portion of the world with little proof for public health gain. The announcement has been postponed until the new year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific pediatric shot schedules in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – usually the purview of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

The appointee has little discernible track record in pharmaceutical research, oversight or management, which has been typical for previous directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Previous heads of CBER would “grasp regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that former directors who headed the center have had.”

This division has an vast range of responsibilities at the FDA, she emphasized.

“Everybody just focuses on the new drug program, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and all of those have to be supervised,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial leadership element to the position, which oversees more than 5,000 personnel. “It’s a massive leadership role, if you do it right,” the former official said.

Response and Controversial Policies

When asked about inquiries about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a press secretary stated that the “concerns rely on incorrect assumptions”.

“This background aligns with the functions of her job,” the representative stated, citing the time Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious one-day drug-approval program that apparently worried her former heads. “By what process are these therapies being picked for this fast-track system? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, with the exception of immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if concerning, track record, Howard said. She published a study using unverified public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new federal leadership included revising regulations for novel immunizations and halting “unnecessary” vaccines, she remarked post-election on a audio program. At the agency, Høeg has according to sources suggested barring teenage boys from receiving Covid vaccines.

“She is an complete ideologue who starts off with her conclusions and tailors the evidence to fit the evidence in a highly disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|